

C. Bernaud¹, C. Allavena¹, S. Pineau², C. Michau³, P. Perré⁴, P. Fialaire⁵, R. Vatan⁶, A.-L. Ruellan⁷, F. Delamarre-Damier^{8,9}, F. Raffi¹, H. Hitoto¹⁰

¹CHU Hôtel-Dieu, Infectious Diseases, Nantes, France, ²COREVIH Pays de la Loire,

³CH, Internal Medicine, St Nazaire, France, ⁴Infectious Diseases, La Roche sur Yon, France

⁵CHU, Infectious Diseases, Angers, France, ⁶CH, Internal Medicine, Laval, France, ⁷CHU Hôtel-Dieu, Pharmacovigilance, Nantes, France,

⁸EHPAD Montfort, Saint Laurent sur Sèvre, France, ⁹CHU, Geriatric Department, Nantes, France, ¹⁰CH, Infectious Diseases, Le Mans, France



Association Gérontologique
de Recherche et d'Enseignement en Ehpad

BACKGROUND

New antiretroviral drugs have helped to improve quality of life and reduce mortality. HIV patients are ageing, with more and more comorbidities, yet few epidemiological, clinical and therapeutic studies are available.

OBJECTIVE

To describe the HIV population aged over 75 and to evaluate their frailty.

INCLUSION / NON-INCLUSION

Inclusion criteria :

- HIV-1 infected adults over 75
- Followed in 6 French centers of the Loire Valley area, France (CHU Nantes, CHU Angers, CHD La Roche sur Yon, CH Le Mans, CH Saint Nazaire, CH Laval)
- Oral informed consent

Non-inclusion criteria

- Patient not willing or refusing to complete the self-administered questionnaire.

RESULTS

Among the 3965 HIV infected patients followed in centers of the Loire Valley area, 65 (1,6%) were aged over 75, 51 were included.

Socio-demographic characteristics

	n (%)
Age (years), median [IQR]	78.7 [76.2;81.7]
Male	38 (74.5)
Country of birth	
France	42 (82)
Subsaharian Africa	4 (7.8)
Others	5 (9.8)
HIV transmission risk category	
Heterosexual	19 (37.3)
MSM - Bisexual	21 (41.2)
Others	11 (21.6)
Education level	
Primary / no diploma	12 (28.5)
School-leaving diploma	26 (62.0)
High school level	4 (9.5)
Living at home*	50 (98.0)
Living single	29 (60.4)
Tobacco use	3 (6.3)
Alcohol consumption (<20 to 50g/day)	12 (25)

*1 patient in nursing home


Immuno-virologic characteristics

	n (%)
HIV-1	51 (100)
Nadir CD4 (cells/mm ³), median [IQR]	181 [73.6 ; 347]
CDC stage C	18 (35.3)
HCV and/or HBV co-infection	4 (7.8)
At HIV diagnosis	
Age, median [IQR]	61.0 [55.4;66.7]
CD4 count (cells/mm ³), median [IQR]	239 [99.6;496.0]
CV (log copies/mL), median [IQR]	5.1 [4.5;5.7]
At last visit	
Time since HIV diagnosis (years), median [IQR]	18.8 [12.5;21.9]
CD4/mm ³ , median [IQR]	564.8 [441;697]
Undetectable HIV viral load	50 (98.0)
Duration of undetectable HIV viral load (years), median [IQR]	7.3 [3.4;10.3]
CD4/CD8 ratio ≥ 1	16 (31.4)
CD4 ≥ 500/mm ³ et CD4/CD8 ≥ 1	13 (25.5)
CMV+ status	40 (78.4)




Antiretroviral history and current ART regimen

	n (%)
On ART	51 (100)
Age at ART initiation, median [IQR]	63.3 (57.8;68.9)
Duration of ART (years), median [IQR]	17.2 [10.2;20.0]
Number of ART regimens, median [IQR]	5 (3;7)
Number of ARV, median [IQR]	2 (1;3)
Current ARV therapy	
2 NRTI + 1 NNRTI	28 (54.9)
2 NRTI + 1 INI	9 (17.7)
2 NRTI + 1 bPI	4 (7.8)
ARV therapy without INTI and bPI	4 (7.8)

Comorbidities



Simplified Geriatric Assessment



CONCLUSION

- Ageing HIV patients are well managed and virologically controlled for their HIV infection.
- The prevalence of geriatric syndromes is high (26%) and makes the ageing HIV population vulnerable.
- The burden of polypharmacy is increasing and can lead to potential related adverse outcomes.
- Coordinated management of HIV infection and geriatric approach is the key to support these patients.

ACKNOWLEDGMENTS

To all study patients and COREVIH's teams : **Nantes** : F. Raffi, E. Billaud, V. Reliquet, C. Allavena, N. Hall, F. Vivrel, C. Brunet-Cartier, B. Bonnet, P. Morineau-Le Houssine, S. Bouchez, M. Lefebvre, D. Boutoille, S. Pineau, C. Biron, M. Besnier, F. Sauser, P. Point, O. Aubry, O. Grossi, C. Queltier, M. Colas, C. Supiot, H. Hüe, M. Cavellec, A. Soria, S. Delarue, J. Orain, S. Sécher-Pineau, T. Jovelin; **Angers** : J.M. Chennebault, V. Rabier, P. Fialaire, Y.M. Vandamme, P. Abgueguen, S. Rehaim; **La Roche sur Yon** : P. Perré, T. Guimard, S. Léautez, J.L. Esnault, O. Bollengier-Stragier, L. Lainé, H. Durand, A. Pageot, C. Garnier; **Le Mans** : H. Hitoto, L. Perez, N. Crochette, M. Delemotte, S. Blanchi, N. Varache, N. Qatib; **Saint Nazaire** : C. Michau, C. Grand-Courault; **Laval** : R. Vatan.

Camille BERNAUD – Service Maladies Infectieuses – Hôtel Dieu - CHU de Nantes – Place Alexis Ricordeau – 44035 Nantes Cedex 1 – camille.bernaud@chu-nantes.fr